The Global Cardiac POC Testing Devices Market was valued at US$ 2,104.1 million in 2015 and is projected to expand at a CAGR of 7.1% during the forecast period (2017–2025). Rising incidence of unhealthy lifestyle related disorders such as peripheral disease, coronary heart disease, cardiac arrest and the enhancing healthcare infrastructure are expected to be major factors driving growth of the global cardiac POC testing devices market over the foreseeable future. According to FH Foundations, a patient-centered organization devoted to research and education of Familial Hypercholesterolemia (FH), 1 in 200-500 people suffered from familial hypercholesterolemia globally, in 2015. Demand for testing cholesterol levels among individuals has increased with increasing population, thereby leading propelling the overall growth of the cardiac POC testing devices market. According to the World Health Organization (WHO), 2016, one-third of ischemic heart disease cases are attributed to high cholesterol levels. Increasing cases of high cholesterol is estimated to cause 2.6 million deaths and 29.7 million disability. Cardiac POC testing devices provide easy-to-use system with the correct assessment of the cholesterol levels. Global healthcare company Abbott Laboratories has acquired cardiac device maker St. Jude Medical, in the stock deal of US$ 25 billion in January 2017. The collaboration has aimed portfolio of leading science-based offerings in diagnostics as well as POC testing devices.
Browse 54 Market Data Tables and 35 Figures spread through 140 Pages and in-depth TOC on Cardiac POC Testing Devices market, by product type (cardiac markers test and analyzers), by end-user (research laboratories, hospitals, ambulatory surgical centers, diagnostic laboratories, and others), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2025
To know the latest trends and insights prevalent in the cardiac POC testing devices market, click the link:
https://www.coherentmarketinsights.com/market-insight/cardiac-poc-testing-devices-market-192
According to World Health Organizations (WHO), 2017, cardiovascular disorder is the major cause of death worldwide. According to the reports, around 17.7 million people died due to cardiovascular disease, representing 31% of the deaths worldwide. The cardiac POC testing device are used to diagnose cardiovascular ailments such as coronary syndromes, heart failure, and myocardial infarction. Cardiac POC testing devices detects enzymes released during heart failure and in vital cardiac circumstances such as synthesizing troponin, kinase, brain natriuretic peptides, and lactate dehydrogenase isoenzymes. Moreover, these tests assist physicians in distinguishing between angina and myocardial infarction, which are two of the major causes of heartache and death. Market players are focused on developing novel testing device to enable easy diagnosis. For instance, Abbott Laboratories launched a software Firmware in July 2017, which is embedded in the cardiac testing device to control cardiac rhythm.
Key Takeaways of the Cardiac POC Testing Devices Market:
- The global cardiac POC testing devices market is expected to expand at a CAGR of 7.1% during the forecast period (2017–2025) due to the high global demand.
- Among product type, the cardiac markers test holds a dominant position in the market, as this test diagnoses activity of the cardiovascular system while performing daily activities.
- Hospitals and research laboratories are the major end-users of cardiac POC testing devices market, as these tests offer reliability and accuracy with periodic measurements of physiological and diagnostic parameters such as blood gas analysis, activated clotting time for high dose, activated clotting time for high dose heparin monitoring occult blood, and hemoglobin diagnosis.
- Some of the major players involved in global cardiac POC testing devices market are Abbott Laboratories,., BG Medicine Inc., Roche Diagnostics, , Inc., Medtronic Inc., and Seimens Healthineers.
